115 related articles for article (PubMed ID: 35142429)
1. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression.
Lin ZY; Yeh ML; Huang CI; Chen SC; Huang CF; Huang JF; Dai CY; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2022 Feb; 38(2):157-164. PubMed ID: 35142429
[TBL] [Abstract][Full Text] [Related]
2. Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma.
Lin ZY; Yeh ML; Huang CI; Liang PC; Hsu PY; Chen SC; Huang CF; Huang JF; Dai CY; Yu ML; Chuang WL
Biomed Pharmacother; 2022 Sep; 153():113540. PubMed ID: 36076618
[TBL] [Abstract][Full Text] [Related]
3. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
4. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
6. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
7. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
[TBL] [Abstract][Full Text] [Related]
8. [YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells].
Guo LW; Shao GL; Luo J; Hao WY; Yao Z; Zheng JP
Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):818-823. PubMed ID: 30481931
[No Abstract] [Full Text] [Related]
9. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Yao X; Zhao CR; Yin H; Wang K; Gao JJ
Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
[TBL] [Abstract][Full Text] [Related]
11. Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.
Lin ZY; Chuang WL
Biomed Pharmacother; 2017 Feb; 86():27-31. PubMed ID: 27936391
[TBL] [Abstract][Full Text] [Related]
12. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
13. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
[TBL] [Abstract][Full Text] [Related]
14. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na
Jiang W; Li G; Li W; Wang P; Xiu P; Jiang X; Liu B; Sun X; Jiang H
Sci Rep; 2018 Jun; 8(1):9706. PubMed ID: 29946188
[TBL] [Abstract][Full Text] [Related]
15. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Wu CH; Wu X; Zhang HW
J Surg Res; 2016 Dec; 206(2):371-379. PubMed ID: 27884331
[TBL] [Abstract][Full Text] [Related]
18. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
19. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
20. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
